Pfenex | Evaluate

August 12, 2020

Contingent value is back in vogue

This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.

September 27, 2019

Go or no go? Novartis eyes a big new growth driver

The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.

June 27, 2019

As Genfit deals and Conatus folds, Nash plays on

A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…

May 15, 2018

Pfenex readies to swim upstream with Forteo copycat

April 18, 2017

A dry run for Novartis and Allergan’s liver disease assets

May 08, 2015

No clinical assets? No problem

April 10, 2015

Good times roll in Q1 as mid and small cap winners outnumber losers

February 16, 2015

With FDA action nearing biosimilar agents begin to shake US market

October 02, 2014

Evaluate

Contingent value is back in vogue

Go or no go? Novartis eyes a big new growth driver

As Genfit deals and Conatus folds, Nash plays on

Pfenex readies to swim upstream with Forteo copycat

A dry run for Novartis and Allergan’s liver disease assets

No clinical assets? No problem

Good times roll in Q1 as mid and small cap winners outnumber losers

With FDA action nearing biosimilar agents begin to shake US market

IPOs surge in Q3 as investor enthusiasm shows no sign of waning

Latest Reports

H1 Round Up: The haves and the have-nots

ADA/EASL eBook

Editor's Picks

Astrazeneca and Daiichi’s big reveal disappoints

Pharma finds a way to gain weight

Protagonist investors flake as psoriasis pill disappoints

Approaching datasets for big pharma

Nkarta goes back to basics